Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.

Shiryaev N, Pikman R, Giladi E, Gozes I.

Curr Pharm Des. 2011;17(25):2603-12. Review.

PMID:
21728979
2.

NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).

Gozes I, Divinski I, Piltzer I.

BMC Neurosci. 2008 Dec 10;9 Suppl 3:S3. doi: 10.1186/1471-2202-9-S3-S3.

3.

NAP alpha-aminoisobutyric acid (IsoNAP).

Gozes I, Schirer Y, Idan-Feldman A, David M, Furman-Assaf S.

J Mol Neurosci. 2014 Jan;52(1):1-9. doi: 10.1007/s12031-013-0103-8.

PMID:
24458740
4.

Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).

Gozes I.

Curr Pharm Des. 2011;17(31):3413-7. Review.

PMID:
21902667
5.

ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.

Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I.

Mol Psychiatry. 2017 Sep;22(9):1335-1344. doi: 10.1038/mp.2016.255. Epub 2017 Jan 24.

PMID:
28115743
6.
7.

D-SAL and NAP: Two Peptides Sharing a SIP Domain.

Gozes I, Sragovich S, Schirer Y, Idan-Feldman A.

J Mol Neurosci. 2016 Jun;59(2):220-31. doi: 10.1007/s12031-015-0701-8.

PMID:
26816081
8.

Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).

Gozes I, Iram T, Maryanovsky E, Arviv C, Rozenberg L, Schirer Y, Giladi E, Furman-Assaf S.

J Alzheimers Dis. 2014;40 Suppl 1:S23-36. doi: 10.3233/JAD-131664.

PMID:
24503616
9.

Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.

Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, Gozes I.

J Pharmacol Exp Ther. 2007 Nov;323(2):438-49. Epub 2007 Aug 24.

10.

The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Oz S, Ivashko-Pachima Y, Gozes I.

PLoS One. 2012;7(12):e51458. doi: 10.1371/journal.pone.0051458. Epub 2012 Dec 14.

11.

The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.

Gozes I, Divinski I.

J Alzheimers Dis. 2004 Dec;6(6 Suppl):S37-41.

PMID:
15665412
13.

A novel peptide prevents death in enriched neuronal cultures.

Zemlyak I, Furman S, Brenneman DE, Gozes I.

Regul Pept. 2000 Dec 22;96(1-2):39-43.

PMID:
11102650
14.

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.

Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I.

Neurobiol Dis. 2009 May;34(2):381-8. doi: 10.1016/j.nbd.2009.02.011. Epub 2009 Mar 2.

PMID:
19264130
15.

Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).

Magen I, Gozes I.

Neuropeptides. 2013 Dec;47(6):489-95. doi: 10.1016/j.npep.2013.10.011. Epub 2013 Oct 24. Review.

PMID:
24210139
16.

The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.

Gozes I.

Biol Chem. 2016 Mar;397(3):177-84. doi: 10.1515/hsz-2015-0152. Review.

PMID:
25955282
17.

Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss.

Zhou FC, Fang Y, Goodlett C.

Alcohol Clin Exp Res. 2008 Aug;32(8):1361-71. doi: 10.1111/j.1530-0277.2008.00722.x. Epub 2008 Jun 28.

18.

ADNP: in search for molecular mechanisms and innovative therapeutic strategies for frontotemporal degeneration.

Gozes I, Ivashko-Pachima Y.

Front Aging Neurosci. 2015 Oct 29;7:205. doi: 10.3389/fnagi.2015.00205. eCollection 2015. Review.

19.

NAP (davunetide) provides functional and structural neuroprotection.

Gozes I.

Curr Pharm Des. 2011;17(10):1040-4. Review.

PMID:
21524250
20.

Activity-dependent neuroprotective protein: from gene to drug candidate.

Gozes I.

Pharmacol Ther. 2007 May;114(2):146-54. Epub 2007 Feb 1. Review.

PMID:
17363064

Supplemental Content

Support Center